Thousands of young people across England are set to be offered a two-dose vaccine against meningococcal B disease (MenB) as part of a new, one-off vaccination programme. This initiative, launching ahead of the 2026 academic year, aims to protect Year 13 pupils and individuals under 25 who are starting university or residential further education for the first time this autumn.
The vaccination schedule will involve two doses, with the first being administered from July and the second in August. This timing is crucial as close and prolonged contact in university halls and social settings can significantly increase the risk of contracting MenB disease. International students under 25 beginning their first year of university are advised to receive their initial dose in their home country where feasible.
Meningococcal disease is a life-threatening condition that can lead to severe, life-changing disabilities such as amputations, hearing loss, and brain damage. It is fatal in approximately 10% of cases. The bacteria causing meningitis can spread through close contact, including kissing, sharing drinks or vapes, or prolonged proximity in shared living environments. Data from the UK Health Security Agency (UKHSA) indicates there were 313 confirmed cases of Meningococcal Group B (MenB) in England during 2024/25, representing around 83% of all invasive meningococcal disease (IMD) cases. These cases disproportionately affect young adults and teenagers, alongside infants who already receive the vaccine through the routine NHS schedule.
The decision to implement this one-off programme follows a significant MenB outbreak in Kent earlier this year, described as the fastest growing and largest ever seen in the UK. While the response to that specific incident has concluded, there have also been more clusters than usual this year, some of which have been larger than anticipated. This has prompted the government to monitor and assess new evidence regarding potential changes in how MenB affects people and whether further vaccination responses are required.
Secretary of State for Health and Social Care, James Murray, stated that the Kent outbreak and recent clusters suggest a possible shift in the way MenB affects individuals. He emphasised the immediate action being taken to protect young people at highest risk as they enter university and residential colleges this autumn. The programme specifically targets individuals who complete year 13 in summer 2026, born between 1st September 2007 and 31st August 2008, as well as those under 25 starting university or residential further education settings for the first time in autumn 2026. UKHSA estimates that first-year university students face a substantially greater relative risk of invasive MenB disease compared to their peers, with cases typically peaking between October and November each year. The vaccination programme aims to mitigate this risk, offering peace of mind to students and their families.
This proactive measure aligns with public health efforts to prevent serious illness and larger outbreaks of the disease. While this is a one-off programme, the government will continue to evaluate the evolving situation of MenB in the UK. Individuals eligible for the vaccine are strongly encouraged to come forward for both doses during July and August to ensure maximum protection before the academic year commences.
Source: UK Health Security Agency (UKHSA)